Aug 31, 2022
Normax plans to list in the near future on the new SIX Sparks exchange for high-growth SMEs by SIX Swiss Exchange. Normax SPVs (10) are planned to be listed in 2023 on SIX Sparks or the SIX Digital Exchange (SDX). SIX SparksSIX Digital Exchange...Aug 31, 2022
Normax Press Release Normax secures €300,000,000 capital commitment from Global Emerging Markets (GEM) for research and development and manufacturing of mRNA Vaccines for transformative global social impact Normax plans to use capital finance to scale mRNA Vaccine...Aug 31, 2022
Abstract. The SARS-CoV-2 pandemic has generated a renaissance in vaccinology, with COVID-19 mRNA vaccines delivering a “digital code” of the viral antigen with no need to purify proteins or inactivate pathogens. Vaccines 2020: The era of the digital vaccine is here...Aug 31, 2022
Normax is in the business of mRNA vaccine Research, Development and Manufacturing. Normax has secured a €300,000,000 capital commitment from a $3.4Bn cornerstone institutional investor for development of mRNA Vaccines and Vax Factory Manufacturing for Transformative...Aug 31, 2022
With an early stage budget of €25,000,000 each, Normax is currently developing mRNA Vax Factories planned to be located in: Ireland Switzerland The United Kingdome The United States Open Allocation It takes 18-24 months from launch to deliver and deploy a regulatory...